Corcept Therapeutics, Inc. (NASDAQ:CORT)

CAPS Rating: 2 out of 5

A pharmaceutical company which is engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases.

Recs

3
Player Avatar zzlangerhans (99.82) Submitted: 12/22/2009 1:01:09 PM : Underperform Start Price: $2.61 CORT Score: +5.23

Corcept continues to flog Corlux, its pipeline in a teacup. The stock continues to get diluted as the phase III study of Corlux in Cushing's syndrome approaches a topline data release in mid-2010. As there is minimal clinical data for efficacy in Cushing's to support the phase III study, I'm not going to get my buffalo hump in a lather over it. The phase III study in psychotic depression is a joke, with obvious enrollment issues in the wake of multiple prior failures for the same indication.

Member Avatar furorimpius (< 20) Submitted: 1/12/2010 8:46:04 PM
Recs: 1

I wouldn't count mifepristone out wrt treating Cushing's syndrome, or at least acute cortisol-induced psychosis. Especially in non-iatrogenic cases, when it me be difficult to treat the primary cause of Cushing's, perhaps if it's caused by an andrenal neoplasm, mifepristone may be the best option.

Featured Broker Partners


Advertisement